ArticleDiagnostics (Basel, Switzerland)2018
Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease.
Article in Diagnostics (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Plasma proteome signatures of ASK1 inhibition by selonsertib associate with efficacy in the MOSAIC randomized trial for diabetic kidney disease.BMC nephrology · 2025Trial
- Circulating Mycobiota Signatures and Cardiovascular Mortality among Patients Undergoing Hemodialysis.Journal of the American Society of Nephrology : JASN · 2026Article
- Analysis of blood proteome in influenza-infected patients reveals new insights into the host response signatures distinguishing mild severe infections.Frontiers in immunology · 2025Article
- A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver.Cell reports. Medicine · 2024Article
- Protein biomarker signatures of preeclampsia - a longitudinal 5000-multiplex proteomics study.Scientific reports · 2024Article
- Article
- Circulating microRNA Profiles for Premature Cardiovascular Death in Patients with Kidney Failure with Replacement Therapy.Journal of clinical medicine · 2023Article
- Proteomics Analysis of Genetic Liability of Abdominal Aortic Aneurysm Identifies Plasma Neogenin and Kit Ligand: The ARIC Study.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- Evaluation of a large-scale aptamer proteomics platform among patients with kidney failure on dialysis.PloS one · 2023Article
- Proteomic profiling identifies novel proteins for genetic risk of severe COVID-19: the Atherosclerosis Risk in Communities Study.Human molecular genetics · 2022Article
- Analytical Considerations of Large-Scale Aptamer-Based Datasets for Translational Applications.Cancers · 2022Review
- Nucleic Acid Nanotechnology for Diagnostics and Therapeutics in Acute Kidney Injury.International journal of molecular sciences · 2022Review
- Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study).The American journal of cardiology · 2021Article
- Circulating Microbial Signatures and Cardiovascular Death in Patients With ESRD.Kidney international reports · 2021Article
- Comprehensive aptamer-based screen of 1317 proteins uncovers improved stool protein markers of colorectal cancer.Journal of gastroenterology · 2021Article
- Accelerating Biomarker Discovery Through Electronic Health Records, Automated Biobanking, and Proteomics.Journal of the American College of Cardiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
End stage renal disease (ESRD) is characterized by complex metabolic abnormalities, yet the clinical relevance of specific biomarkers remains unclear. The development of multiplex diagnostic platforms is creating opportunities to develop novel diagnostic and therapeutic approaches. SOMAscan is an innovative multiplex proteomic platform which can measure >1300 proteins. In the present study, we performed SOMAscan analysis of plasma samples and validated the measurements by comparison with selected biomarkers. We compared concentrations of SOMAscan-measured prostate specific antigen (PSA) between males and females, and validated SOMAscan concentrations of fibroblast growth factor 23 (FGF23), FGF receptor 1 (FGFR1), and FGFR4 using Enzyme-Linked immunosorbent assay (ELISA). The median (25th and 75th percentile) SOMAscan PSA level in males and females was 4304.7 (1815.4 to 7259.5) and 547.8 (521.8 to 993.4) relative fluorescence units (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.